NASDAQ · Biotechnology

MiNK Therapeutics, Inc. (INKT) Stock

$10.97 -0.95% NASDAQ: INKT Healthcare

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials.

Valuation

MetricValue
Price$10.97
Market Cap$54.63M
P/E Ratio-3.91
P/B Ratio-4.19
P/S Ratio0.00
EPS (TTM)$-2.93
52-Week High$19.61
52-Week Low$8.48
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE76.02%
ROA-120.17%
ROCE-415.48%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.36
Current Ratio1.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-31.0M$-23.0M$-11.0M$-12.0M
Net Profit$-30.0M$-28.0M$-22.0M$-11.0M$-12.0M
EPS$-9.03$-8.31$-6.54$-2.80$-2.93
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$40.0M$21.0M$5.0M$6.0M$14.0M
Total Liabilities$16.0M$22.0M$23.0M$25.0M$28.0M
Cash$39.0M$20.0M$3.0M$5.0M$13.0M
Borrowings$0$0$0$5.0M$5.0M

Latest News

Dow Jones Futures: Micron, Sandisk, Google Lead AI Sell-Off, Netflix Dives Late; SpaceX Starship Launch Scrubbed Investor's Business Daily · Jul 17, 2026 Lemonade To Announce Second Quarter 2026 Financial Results PR Newswire · Jul 17, 2026 2 Reasons to Like BDC (and 1 Not So Much) StockStory · Jul 17, 2026 Taco Bell removes lettuce in some states over cyclosporiasis link Reuters · Jul 17, 2026 Brookfield Wealth Solutions Announces Shareholder Approval of Transaction to Simplify Corporate Structure and Results of 2026 Annual General and Special Meeting GlobeNewswire · Jul 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-19.0M$-16.0M$-10.0M$-6.0M
Investing Cash Flow$0$-1.0M$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$36.0M$-19.0M$-16.0M$1.0M$9.0M
Free Cash Flow$-13.0M$-19.0M$-16.0M$-10.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.32
EV / EBITDA-3.52
FCF Yield-10.98%
Quick Ratio1.08
Interest Coverage0.00
Return 1Y-59.71%
Return 3Y-38.33%
Return 5Y—

Ownership

Insiders Held60.67%
Institutions Held2.63%
Institutions Float Held6.68%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC59,3642026-03-31
Geode Capital Management, LLC17,3452026-03-31
Longbow Finance Sa16,6672026-03-31
UBS Group AG15,2022026-03-31
Vanguard Fiduciary Trust Co8,2872026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CRVO $2.56 -3.76% -1.09 $23.70M 0.00%
EQ $2.57 +3.21% -5.28 $91.29M 0.00%
GANX $1.73 -6.99% -2.70 $73.79M 0.00%
HOWL $0.40 -3.04% -0.33 $19.54M 0.00%
IOBTIO Biotech, Inc. $0.01 -27.59% -0.01 $885690 0.00%

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

MiNK Therapeutics, Inc. is led by CEO Jennifer S. Buell, employs 23 people, headquartered in US, publicly traded since 2021.

MiNK Therapeutics, Inc. (INKT) stock trades at $10.97 with a market capitalization of $54.63M. The stock is valued at a price-to-earnings (P/E) ratio of -3.91, price-to-book of -4.19, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.48 and $19.61, and currently trades 44.1% below its 52-week high.

On profitability, MiNK Therapeutics, Inc. generates a return on equity (ROE) of 76.02% — well above the market average, a sign of a high-quality business, return on capital employed of -415.48%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: minktherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides